Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA.

Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.

2.

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.

Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R.

Clin Cancer Res. 2017 Jul 1;23(13):3416-3427. doi: 10.1158/1078-0432.CCR-16-2000. Epub 2017 Jan 9.

3.

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.

Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA.

MAbs. 2014;6(6):1571-84. doi: 10.4161/19420862.2014.975660.

4.

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'Acqua W, Damschroder M, Hammond SA.

PLoS One. 2012;7(5):e36412. doi: 10.1371/journal.pone.0036412. Epub 2012 May 4.

5.

Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation.

Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, Kelly K, Merlino G.

Oncogene. 2010 Apr 22;29(16):2449-56. doi: 10.1038/onc.2009.521. Epub 2010 Feb 1. Erratum in: Oncogene. 2011 Apr 14;30(15):1850.

6.

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.

J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70.

PMID:
19342971
7.

TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.

Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y, Kelly K.

BMC Cancer. 2008 Jul 2;8:189. doi: 10.1186/1471-2407-8-189.

8.

HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.

Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2005 Aug;289(2):C462-70. Epub 2005 Mar 30.

9.

Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts.

Hung RJ, Hsu IaW, Dreiling JL, Lee MJ, Williams CA, Oberst MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2004 May;286(5):C1159-69.

10.

Characterization of matriptase expression in normal human tissues.

Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY.

J Histochem Cytochem. 2003 Aug;51(8):1017-25.

PMID:
12871983
11.

Possible role of matriptase in the diagnosis of ovarian cancer.

Johnson MD, Oberst MD, Lin CY, Dickson RB.

Expert Rev Mol Diagn. 2003 May;3(3):331-8. Review.

PMID:
12779007
12.

The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.

Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY.

J Biol Chem. 2003 Jul 18;278(29):26773-9. Epub 2003 May 8.

13.

Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC.

Clin Cancer Res. 2002 Apr;8(4):1101-7.

14.
15.

The encephalomyocarditis virus 3C protease is rapidly degraded by an ATP-dependent proteolytic system in reticulocyte lysate.

Oberst MD, Gollan TJ, Gupta M, Peura SR, Zydlewski JD, Sudarsanan P, Lawson TG.

Virology. 1993 Mar;193(1):28-40.

PMID:
8382397

Supplemental Content

Loading ...
Support Center